CA3023257A1 - Dry powder treprostinil for the treatment of pulmonary hypertension - Google Patents

Dry powder treprostinil for the treatment of pulmonary hypertension Download PDF

Info

Publication number
CA3023257A1
CA3023257A1 CA3023257A CA3023257A CA3023257A1 CA 3023257 A1 CA3023257 A1 CA 3023257A1 CA 3023257 A CA3023257 A CA 3023257A CA 3023257 A CA3023257 A CA 3023257A CA 3023257 A1 CA3023257 A1 CA 3023257A1
Authority
CA
Canada
Prior art keywords
treprostinil
dose
micrograms
dry powder
particles
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3023257A
Other languages
English (en)
French (fr)
Inventor
Robert Frank Roscigno
Brian T. FARRER
Jacob J. SPRAGUE
Benjamin Maynor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Liquidia Technologies Inc
Original Assignee
Liquidia Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60203775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA3023257(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Liquidia Technologies Inc filed Critical Liquidia Technologies Inc
Publication of CA3023257A1 publication Critical patent/CA3023257A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA3023257A 2016-05-05 2017-05-05 Dry powder treprostinil for the treatment of pulmonary hypertension Pending CA3023257A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662332013P 2016-05-05 2016-05-05
US62/332,013 2016-05-05
US201662404960P 2016-10-06 2016-10-06
US62/404,960 2016-10-06
US201662440078P 2016-12-29 2016-12-29
US62/440,078 2016-12-29
US201762472204P 2017-03-16 2017-03-16
US62/472,204 2017-03-16
PCT/US2017/031301 WO2017192993A1 (en) 2016-05-05 2017-05-05 Dry powder treprostinil for the treatment of pulmonary hypertension

Publications (1)

Publication Number Publication Date
CA3023257A1 true CA3023257A1 (en) 2017-11-09

Family

ID=60203775

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3023257A Pending CA3023257A1 (en) 2016-05-05 2017-05-05 Dry powder treprostinil for the treatment of pulmonary hypertension

Country Status (7)

Country Link
US (9) US10898494B2 (cg-RX-API-DMAC7.html)
EP (1) EP3452170A4 (cg-RX-API-DMAC7.html)
JP (3) JP2019519489A (cg-RX-API-DMAC7.html)
AU (3) AU2017261317A1 (cg-RX-API-DMAC7.html)
CA (1) CA3023257A1 (cg-RX-API-DMAC7.html)
IL (3) IL319790A (cg-RX-API-DMAC7.html)
WO (1) WO2017192993A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
EP2861296A1 (en) * 2012-06-15 2015-04-22 Case Western Reserve University Therapy delivery devices and methods for non-damaging neural tissue conduction block
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
BR122019026637B1 (pt) 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
US10343979B2 (en) 2014-11-18 2019-07-09 Insmed Incorporated Methods of manufacturing treprostinil and treprostinil derivative prodrugs
US20190321290A1 (en) * 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
SG11202011045VA (en) * 2018-05-07 2020-12-30 Pharmosa Biopharm Inc Pharmaceutical composition for controlled release of treprostinil
CA3102967A1 (en) * 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
CN119632930A (zh) 2019-04-29 2025-03-18 英斯梅德股份有限公司 曲前列素前药的干粉组合物及其使用方法
CN114401716A (zh) 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物
IL296567A (en) 2020-04-17 2022-11-01 United Therapeutics Corp Terfostinil for use in the treatment of interstitial lung disease
CN116437906B (zh) * 2020-10-28 2026-07-03 英斯梅德股份有限公司 曲前列环素前药的干粉组合物和其使用方法
CA3235985A1 (en) * 2021-10-27 2023-05-04 Mannkind Corporation Methods and compositions for treating pulmonary hypertension
WO2023154705A1 (en) * 2022-02-08 2023-08-17 United Therapeutics Corporation Treprostinil iloprost combination therapy
EP4516297A4 (en) 2022-04-29 2026-02-25 Zhaoke pharmaceutical guangzhou co ltd Treprostinil Gentle Inhalation Mist
WO2025174856A1 (en) * 2024-02-12 2025-08-21 Mannkind Corporation Process for making a composition for pulmonary inhalation

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS56122328A (en) 1980-02-29 1981-09-25 Sumitomo Chem Co Ltd Crystalline amine salt of methanoplastocyclin, its preparation and purifying method
US4306075A (en) 1980-03-28 1981-12-15 The Upjohn Company Composition and process
GB8814438D0 (en) 1988-06-17 1988-07-20 Wellcome Found Compounds for use in medicine
US5441060A (en) * 1993-02-08 1995-08-15 Duke University Dry powder delivery system
CH687615A5 (de) * 1994-09-07 1997-01-15 R W Johnson Pharmaceutical Res Tropen-Verpackung.
US6503480B1 (en) 1997-05-23 2003-01-07 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6441245B1 (en) 1997-10-24 2002-08-27 United Therapeutics Corporation Process for stereoselective synthesis of prostacyclin derivatives
US20030118567A1 (en) 1999-03-26 2003-06-26 Stewart Duncan John Cell-based therapy for the pulmonary system
US6521212B1 (en) * 1999-03-18 2003-02-18 United Therapeutics Corporation Method for treating peripheral vascular disease by administering benzindene prostaglandins by inhalation
US6858199B1 (en) 2000-06-09 2005-02-22 Advanced Inhalation Research, Inc. High efficient delivery of a large therapeutic mass aerosol
US7305986B1 (en) * 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US6242482B1 (en) 2000-06-05 2001-06-05 United Therapeutics Corporation Prostaglandin compounds and derivatives thereof, compositions containing the same and method of using the same for the treatment of congestive heart failure
EG24184A (en) * 2001-06-15 2008-10-08 Otsuka Pharma Co Ltd Dry powder inhalation system for transpulmonary
US6889690B2 (en) * 2002-05-10 2005-05-10 Oriel Therapeutics, Inc. Dry powder inhalers, related blister devices, and associated methods of dispensing dry powder substances and fabricating blister packages
GB0219511D0 (en) * 2002-08-21 2002-10-02 Norton Healthcare Ltd Method of preparing dry powder inhalation compositions
CN102697790A (zh) 2003-05-22 2012-10-03 联合治疗公司 化合物和释放前列环素类似物的方法
AU2004249166B2 (en) 2003-06-13 2008-10-09 Alkermes, Inc. Low dose pharmaceutical powders for inhalation
US20040265238A1 (en) 2003-06-27 2004-12-30 Imtiaz Chaudry Inhalable formulations for treating pulmonary hypertension and methods of using same
ATE551383T1 (de) 2003-09-23 2012-04-15 Univ North Carolina Photohärtbare perfluorpolyether zur verwendung als neue werkstoffe in mikrofluidischen vorrichtungen
US7199157B2 (en) 2003-12-16 2007-04-03 United Therapeutics Corporation Use of treprostinil to improve kidney functions
CN1917866B (zh) 2003-12-16 2010-12-15 联合治疗公司 曲前列环素或它的衍生物,或其药学上可接受的盐在制备治疗和预防缺血性损害的药物中的用途
WO2005101466A2 (en) 2003-12-19 2005-10-27 The University Of North Carolina At Chapel Hill Methods for fabricating isolated micro- and nano- structures using soft or imprint lithography
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
WO2007021762A2 (en) 2005-08-09 2007-02-22 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
DE602005020269D1 (de) 2004-04-12 2010-05-12 United Therapeutics Corp Verwendung von treprostinil zur behandlung von neuropathischen diabetischen fussgeschwüren
CA2574958A1 (en) 2004-07-26 2006-02-09 Cotherix, Inc. Treatment of pulmonary hypertension by inhaled iloprost with a microparticle formulation
HUE025151T2 (en) 2004-08-23 2016-01-28 Mannkind Corp Diceto-piperazine salts for drug delivery
WO2007133808A2 (en) 2006-05-15 2007-11-22 Liquidia Technologies, Inc. Nano-particles for cosmetic applications
CA2654492C (en) 2006-05-15 2017-06-27 United Therapeutics Corporation Treprostinil administration using a metered dose inhaler
CA2655477C (en) 2006-06-16 2015-05-05 Cipla Limited Vibration assisted release of encapsulated inhalable powder
US20090036465A1 (en) 2006-10-18 2009-02-05 United Therapeutics Corporation Combination therapy for pulmonary arterial hypertension
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
WO2009049299A1 (en) 2007-10-12 2009-04-16 Liquidia Technologies, Inc. System and method for producing particles and patterned films
WO2009078965A1 (en) 2007-12-17 2009-06-25 United Therapeutics Corporation An improved process to prepare treprostinil, the active ingredient in remodulin
US20110151015A1 (en) 2008-03-04 2011-06-23 Liquikia Technologies, Inc. Immunomodulator particles and methods of treating
EP2257326A2 (en) * 2008-03-21 2010-12-08 Novartis AG Powder dispersion apparatus
JP6219016B2 (ja) 2008-05-08 2017-10-25 ユナイテッド セラピューティクス コーポレーション トレプロスチニル一水和物
WO2009150136A1 (de) 2008-06-09 2009-12-17 Boehringer Ingelheim International Gmbh Neue einbettungspartikel für die inhalation
WO2009152160A1 (en) * 2008-06-10 2009-12-17 Gilead Sciences, Inc. Inhaled carbaprostacyclin and prostacyclin prodrugs for the treatment of pulmonary arterial hypertension
EP2330893A4 (en) 2008-09-25 2013-01-09 Aradigm Corp DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
CN104162947B (zh) 2008-12-05 2017-04-12 流体科技公司 产生有图案的材料的方法
AU2010259943C1 (en) 2009-06-12 2016-03-03 Mannkind Corporation Diketopiperazine microparticles with defined specific surface areas
US20120114554A1 (en) 2009-07-13 2012-05-10 Liquidia Technologies, Inc. Engineered Aerosol Particles, And Associated Methods
AU2010280684B2 (en) 2009-08-07 2016-07-28 Scipharm Sarl Composition for the treatment of cystic fibrosis
EP2338520A1 (de) 2009-12-21 2011-06-29 Ludwig Maximilians Universität Konjugat mit Zielfindungsligand und dessen Verwendung
US20130209564A1 (en) 2010-02-22 2013-08-15 Shyam M. Rele Polysaccharide Particle Vaccines
CN102869402A (zh) * 2010-04-23 2013-01-09 3M创新有限公司 干粉吸入器组件和容器
CA2726599C (en) 2010-12-30 2017-07-25 Alphora Research Inc. Process for treprostinil salt preparation
PL2663313T3 (pl) 2011-01-13 2019-01-31 SciPharm S.à r.l. Sposób zwiększania wszczepiania hematopoetycznych komórek macierzystych
JP5780775B2 (ja) 2011-02-18 2015-09-16 株式会社Lttバイオファーマ プロスタグランジンi2誘導体を含有するナノ粒子
EP2526926A1 (de) 2011-05-25 2012-11-28 Justus-Liebig-Universität Gießen Biokompatible Nanopolymerpartikel mit Wirkstoffen für die pulmonale Applikation
AU2012296953B2 (en) 2011-08-12 2016-10-20 Ascendis Pharma A/S Sustained release composition of prostacyclin
CA2850484C (en) 2011-09-30 2021-01-26 Bluebird Bio, Inc. Compounds for improved viral transduction
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US9554968B2 (en) 2013-03-11 2017-01-31 Sio2 Medical Products, Inc. Trilayer coated pharmaceutical packaging
CN107875127A (zh) 2012-02-28 2018-04-06 艾塞尤提卡控股公司 可吸入药物组合物
US20150136130A1 (en) * 2012-02-29 2015-05-21 Pulmatrix, Inc. Inhalable dry powders
US10071209B2 (en) 2012-03-15 2018-09-11 Steadymed Ltd. Enhanced infusion-site pain-reduction for drug-delivery devices
CN104684561A (zh) 2012-08-01 2015-06-03 联合治疗公司 利用间充质干细胞的肺动脉高血压的治疗
WO2014085813A1 (en) 2012-11-30 2014-06-05 Insmed Incorporated Prostacylin compositions and methods for using the same
US9505737B2 (en) * 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
WO2014159050A1 (en) 2013-03-14 2014-10-02 United Therapeutics Corporation Solid forms of treprostinil
BR112015023168B1 (pt) 2013-03-15 2021-08-10 Mannkind Corporation Composição de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina cristalina, método de produção de partículas de 3,6-bis(n-fumaril-4-aminobutil)-2,5-dicetopiperazina e uso de uma composição de dicetopiperazina cristalina
ITMI20130572A1 (it) * 2013-04-10 2014-10-11 Eratech Srl Composizione comprendente almeno due polveri secche ottenute per spray dry per aumentare la stabilita' della formulazione
CA2911172C (en) 2013-04-30 2021-10-19 United Therapeutics Corporation Controlled release pharmaceutical formulations
US9349730B2 (en) 2013-07-18 2016-05-24 Globalfoundries Inc. Fin transformation process and isolation structures facilitating different Fin isolation schemes
BR122019026637B1 (pt) * 2013-07-18 2023-09-26 Mannkind Corporation Formulações farmacêuticas de pó seco e método para a fabricação de uma formulação de pó seco
ES2959419T3 (es) * 2013-10-11 2024-02-26 Pulmokine Inc Formulaciones secas por aspersión
US9469600B2 (en) 2013-10-25 2016-10-18 Insmed Incorporated Prostacyclin compounds, compositions and methods of use thereof
GB201400412D0 (en) * 2014-01-10 2014-02-26 Heart Biotech Ltd Pharmaceutical formulations for the treatment of pulmonary arterial hypertension
MX2016010213A (es) 2014-02-07 2017-04-13 Auspex Pharmaceuticals Inc Formulaciones farmaceuticas novedosas.
WO2015138423A1 (en) * 2014-03-11 2015-09-17 Insmed Incorporated Prostacylin compositions and methods for using the same
CA2963085C (en) * 2014-10-07 2023-02-21 Lam Therapeutics, Inc. An inhalable rapamycin formulation for the treatment of pulmonary hypertension
US9643911B2 (en) 2015-06-17 2017-05-09 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
US9394227B1 (en) 2015-06-17 2016-07-19 Corsair Pharma, Inc. Treprostinil derivatives and compositions and uses thereof
IL260823B2 (en) 2016-01-29 2024-08-01 Mannkind Corp Dry powder inhaler
US20190321290A1 (en) 2016-01-29 2019-10-24 Mannkind Corporation Composition and method for inhalation
EP3452170A4 (en) 2016-05-05 2020-04-01 Liquidia Technologies, Inc. TREPROSTINIL IN POWDER FORM FOR TREATING PULMONAL HYPERTENSION
EP3554507A1 (en) 2016-12-14 2019-10-23 Respira Therapeutics, Inc. Methods and compositions for treatment of pulmonary hypertension and other lung disorders
CA3102967A1 (en) 2018-06-07 2019-12-12 Mannkind Corporation Composition and method for inhalation
CN112739679B (zh) 2018-09-18 2024-03-12 伊莱利利公司 曲前列环素的特丁胺盐
JP7365073B2 (ja) 2019-05-21 2023-10-19 ジァンスー フォアフロント ファーマシューティカル カンパニー,リミテッド トレプロスチニルナトリウムの新規な結晶形および製造方法
CN114401716A (zh) 2019-07-22 2022-04-26 纳诺米有限公司 持续释放的曲前列环素-化合物微粒组合物

Also Published As

Publication number Publication date
AU2025204321A1 (en) 2025-06-26
IL262720A (en) 2018-12-31
IL262720B1 (en) 2024-02-01
US20220257608A1 (en) 2022-08-18
IL310250B2 (en) 2025-09-01
EP3452170A1 (en) 2019-03-13
AU2017261317A1 (en) 2018-12-13
US11712442B2 (en) 2023-08-01
IL319790A (en) 2025-05-01
EP3452170A4 (en) 2020-04-01
US11744835B2 (en) 2023-09-05
US20260216209A1 (en) 2026-07-30
IL310250A (en) 2024-03-01
US11744836B2 (en) 2023-09-05
US20190151332A1 (en) 2019-05-23
JP2019519489A (ja) 2019-07-11
US20260216210A1 (en) 2026-07-30
WO2017192993A1 (en) 2017-11-09
US11660304B2 (en) 2023-05-30
US20230346799A1 (en) 2023-11-02
JP2025118785A (ja) 2025-08-13
IL310250B1 (en) 2025-05-01
US20210077504A1 (en) 2021-03-18
US20250332175A1 (en) 2025-10-30
IL262720B2 (en) 2024-06-01
US20210353640A1 (en) 2021-11-18
US20210353641A1 (en) 2021-11-18
AU2023201307A1 (en) 2023-04-06
US12390475B2 (en) 2025-08-19
US10898494B2 (en) 2021-01-26
JP2023071844A (ja) 2023-05-23

Similar Documents

Publication Publication Date Title
US12390475B2 (en) Dry powder treprostinil for the treatment of pulmonary hypertension
RU2275900C2 (ru) Способ высокоэффективной доставки аэрозоля с большой терапевтической массой
AU2003218306B2 (en) Method for administration of growth hormone via pulmonary delivery
ES2859629T3 (es) Formulaciones mejoradas
CN105101955A (zh) 至少包含两种通过喷雾干燥以增加制剂稳定性而得到的干粉的组合物
KR20180002750A (ko) 폐 전달용 졸미트립탄 분말
KR102763099B1 (ko) 폐 투여에 의한 우울증의 치료에 사용하기 위한 건조 분말 케타민 조성물
JP7444864B2 (ja) 肺投与によるうつ病の処置方法における使用のためのケタミン組成物
US20250213803A1 (en) Dry powder formulations, dose containers and inhalers containing the same, and methods
EA046690B1 (ru) Композиция кетамина в виде сухого порошка для применения при лечении депрессии ингаляционным путем
US20050163725A1 (en) Method for administration of growth hormone via pulmonary delivery

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220503

T11 Administrative time limit extension requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T11-T100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUEST RECEIVED

Effective date: 20241002

T13 Administrative time limit extension granted

Free format text: ST27 STATUS EVENT CODE: A-2-2-T10-T13-T101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXTENSION OF TIME FOR TAKING ACTION REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20241003

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT

Effective date: 20241003

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241003

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20241129

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20250203

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250502

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250502

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20250530

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20250530

D15 Examination report completed

Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT

Effective date: 20251010

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION

Effective date: 20260209

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT

Effective date: 20260219

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED

Effective date: 20260219

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260219